Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 2
2020 1
2021 1
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users.
Jensen JT, Archer DF, Westhoff CL, Nelson AL, Graham S, Bernick B. Jensen JT, et al. J Womens Health (Larchmt). 2023 Jul;32(7):808-815. doi: 10.1089/jwh.2022.0264. Epub 2023 May 29. J Womens Health (Larchmt). 2023. PMID: 37253139 Clinical Trial.
Background: We evaluated satisfaction with use of a segesterone acetate and ethinyl estradiol (0.15/0.013 mg) contraceptive vaginal system (CVS) among women who had recently used a monthly contraceptive vaginal ring or contraceptive pills. ...
Background: We evaluated satisfaction with use of a segesterone acetate and ethinyl estradiol (0.15/0.013 mg) contracep …
Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.
Gemzell-Danielsson K, Sitruk-Ware R, Creinin MD, Thomas M, Barnhart KT, Creasy G, Sussman H, Alami M, Burke AE, Weisberg E, Fraser I, Miranda MJ, Gilliam M, Liu J, Carr BR, Plagianos M, Roberts K, Blithe D. Gemzell-Danielsson K, et al. Contraception. 2019 Jun;99(6):323-328. doi: 10.1016/j.contraception.2019.02.001. Epub 2019 Mar 1. Contraception. 2019. PMID: 30831102 Free PMC article. Clinical Trial.
OBJECTIVES: To evaluate safety outcomes from clinical studies of a 12-month contraceptive vaginal system (CVS) releasing an average of segesterone acetate (SA) 150 mcg and ethinyl estradiol (EE) 13 mcg daily. ...
OBJECTIVES: To evaluate safety outcomes from clinical studies of a 12-month contraceptive vaginal system (CVS) releasing an average of se …
Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study.
Simmons KB, Kumar N, Plagianos M, Roberts K, Hoskin E, Han L, Alami M, Creasy G, Variano B, Merkatz R. Simmons KB, et al. Contraception. 2018 Mar;97(3):270-276. doi: 10.1016/j.contraception.2017.10.010. Epub 2017 Oct 31. Contraception. 2018. PMID: 29097225 Clinical Trial.
OBJECTIVES: To evaluate the effects of concurrent administration of three vaginal miconazole nitrate formulations on the absorption and exposure of Nestorone (segesterone acetate) and ethinyl estradiol from a novel contraceptive vaginal ring (NES/EE CVR). ...
OBJECTIVES: To evaluate the effects of concurrent administration of three vaginal miconazole nitrate formulations on the absorption and expo …
Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.
Chen MJ, Creinin MD, Turok DK, Archer DF, Barnhart KT, Westhoff CL, Thomas MA, Jensen JT, Variano B, Sitruk-Ware R, Shanker A, Long J, Blithe DL. Chen MJ, et al. Contraception. 2020 Sep;102(3):168-173. doi: 10.1016/j.contraception.2020.05.004. Epub 2020 May 19. Contraception. 2020. PMID: 32416145 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate serum estradiol (E2) concentrations during use of 90-day contraceptive vaginal rings releasing E2 75, 100, or 200 mcg/day and segesterone acetate (SA) 200 mcg/day to identify a dose that avoids hypoestrogenism. ...IMPLICATIONS: A 90-day contra …
OBJECTIVE: To evaluate serum estradiol (E2) concentrations during use of 90-day contraceptive vaginal rings releasing E2 75, 100, or …
Design of an international male contraceptive efficacy trial using a self-administered daily transdermal gel containing testosterone and segesterone acetate (Nestorone).
Amory JK, Blithe DL, Sitruk-Ware R, Swerdloff RS, Bremner WJ, Dart C, Liu PY, Thirumalai A, Nguyen BT, Anawalt BD, Lee MS, Page ST, Wang C. Amory JK, et al. Contraception. 2023 Aug;124:110064. doi: 10.1016/j.contraception.2023.110064. Epub 2023 May 18. Contraception. 2023. PMID: 37210024 Clinical Trial.
We designed and are currently conducting an international, multicenter, open-label study of self-administration of a daily combined testosterone and segesterone acetate (Nestorone) gel for male contraception. The transdermal approach to male contraception raises novel cons …
We designed and are currently conducting an international, multicenter, open-label study of self-administration of a daily combined testoste …
The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring.
Thompson RL, Hu J, Custodio P, Dart C, Jensen JT. Thompson RL, et al. Contraception. 2022 Apr;108:61-64. doi: 10.1016/j.contraception.2021.12.004. Epub 2021 Dec 28. Contraception. 2022. PMID: 34971614 Clinical Trial.
OBJECTIVES: To determine the incidence of out-of-range segesterone acetate (NES) concentrations in participants of a pharmacokinetic/pharmacodynamic trial of a continuous use contraceptive vaginal ring (CVR) releasing NES and estradiol (E2). ...
OBJECTIVES: To determine the incidence of out-of-range segesterone acetate (NES) concentrations in participants of a pharmacokinetic/ …
Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.
Vieira CS, Fraser IS, Plagianos MG, Burke AE, Westhoff CL, Jensen J, Brache V, Bahamondes L, Merkatz R, Sitruk-Ware R, Blithe DL. Vieira CS, et al. Contraception. 2019 Dec;100(6):438-444. doi: 10.1016/j.contraception.2019.07.145. Epub 2019 Aug 6. Contraception. 2019. PMID: 31398307 Free PMC article. Clinical Trial.
OBJECTIVES: To describe bleeding patterns among users of the segesterone acetate (SA) and ethinyl estradiol (EE) contraceptive vaginal system (CVS), and identify factors associated with unscheduled bleeding/spotting (B/S). ...
OBJECTIVES: To describe bleeding patterns among users of the segesterone acetate (SA) and ethinyl estradiol (EE) contra …
Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.
Plagianos MG, Ramanadhan S, Merkatz RB, Brache V, Friedland BA, Haddad LB. Plagianos MG, et al. Am J Obstet Gynecol. 2024 May;230(5):548.e1-548.e8. doi: 10.1016/j.ajog.2024.01.020. Epub 2024 Jan 29. Am J Obstet Gynecol. 2024. PMID: 38295968 Clinical Trial.
BACKGROUND: The US Food and Drug Administration-approved segesterone acetate and ethinyl estradiol ring-shaped contraceptive vaginal system, known as Annovera (Sever Pharma Solutions/QPharma, Malmo, Sweden), was inserted and removed under a woman's control fo …
BACKGROUND: The US Food and Drug Administration-approved segesterone acetate and ethinyl estradiol ring-shaped contrace …
Factors associated with nonadherence to instructions for using the Nestorone/ethinyl estradiol contraceptive vaginal ring.
Stifani BM, Plagianos M, Vieira CS, Merkatz RB. Stifani BM, et al. Contraception. 2018 May;97(5):415-421. doi: 10.1016/j.contraception.2017.12.011. Epub 2017 Dec 18. Contraception. 2018. PMID: 29269252 Free PMC article. Clinical Trial.
STUDY DESIGN: Data from a multicountry Phase 3 trial of the Nestorone (segesterone acetate)/ethinyl estradiol (NES/EE) contraceptive vaginal ring (CVR) were analyzed. ...
STUDY DESIGN: Data from a multicountry Phase 3 trial of the Nestorone (segesterone acetate)/ethinyl estradiol (NES/EE) …